Phathom Pharmaceuticals, Inc. Free Cash Flow Margin

Free Cash Flow Margin of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow Margin growth rates and interactive chart. Free cash flow margin or Free cash flow-to-sales is a performance ratio that measures operating cash flows after deduction of capital expenditures (free cash flow) relative to sales. Free cash flows (FCF) is an important metric in assessing a company's financial condition and determining its intrinsic valuation. FCF/sales is tracked over time and can be compared to a company's historical record or to peers. Free cash flow is useful because it takes out non-cash items out of earnings and only looks at the underlying operating cash coming in and out of a business minus the necessary capital expenditures.


Highlights and Quick Summary

  • Annual Free Cash Flow Margin for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual Free Cash Flow Margin for 2019 was 0.0% (a NaN% decrease from previous year)
  • Twelve month Free Cash Flow Margin ending September 29, 2021 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Free Cash Flow Margin decreased by NaN% year-over-year
Trailing Free Cash Flow Margin for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow Margin of Phathom Pharmaceuticals, Inc.

Most recent Free Cash Flow Marginof PHAT including historical data for past 10 years.

Interactive Chart of Free Cash Flow Margin of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Free Cash Flow Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0%
2019 0.0%
2018 0.0%

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.